



Journal of the British Thoracic Society

Impact Factor: 8.562

Editors-in-Chief

A Bush (UK)
I Pavord (UK)

Deputy Editors

P Cullinan (UK)
C Lloyd (UK)

Associate Editors

R Beasley (New Zealand)	S Nathan (USA)
A Custovic (UK)	JL Pepin (France)
P Gibson (Australia)	T Sethi (UK)
J Grigg (UK)	D Sin (Canada)
D Halpin (UK)	M Steiner (UK)
ML Han (USA)	D Thickett (UK)
A Jones (UK)	A Torres (Spain)
E Lim (UK)	Z Udawadia (India)
N Maskell (UK)	H Zar (South Africa)

Online Associate Editor

T Fardon (UK)

Statistical Editors

J Gibson (UK)
T McKeever (UK)

Statistician

L Szatkowski (UK)

Journal club Editor

J Quint (UK)

President, British Thoracic Society

A Millar

Editorial Office

Thorax, BMA House, Tavistock Square,
London WC1H 9JR, UK
T: +44 (0)20 7383 6373
E: thorax@bmj.com

Twitter: @ThoraxBMJ

ISSN: 0040-6376 (print)
ISSN: 1468-3296 (online)

Disclaimer: Thorax is owned and published by the British Thoracic Society and BMJ Publishing Group Ltd, a wholly owned subsidiary of the British Medical Association. The owners grant editorial freedom to the Editor of Thorax.

Thorax follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

Thorax is intended for medical professionals and is provided without warranty, express or implied. Statements in the Journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group Ltd, the British Thoracic Society or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group Ltd shall not be liable for any loss, injury or damage resulting from the use of Thorax or any information in it whether based on contract, tort or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2015 BMJ Publishing Group Ltd and the British Thoracic Society. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior permission of Thorax.

Thorax is published by BMJ Publishing Group Ltd, typeset by Techset and printed in the UK on acid-free paper.

Thorax (ISSN No: 0040-6376) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431. POSTMASTER: send address changes to Thorax, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

i1 Summary of recommendations and good practice points

i5 Introduction

- i5 Target audience for the guideline
- i5 Groups covered
- i5 Scope of the guideline
- i5 Areas not covered by the guideline
- i5 Methodology
- i6 Clinical questions and literature search
- i6 Appraisal of the literature
- i6 Considered judgement and grading of evidence
- i6 Drafting the guideline
- i7 Declarations of Interest
- i7 Acknowledgements
- i7 Audit and research recommendations
- i7 Glossary/Abbreviations and symbols

i8 Long Term Oxygen Therapy

i8 Evidence for use of LTOT in patients with COPD

- i8 Survival benefit in COPD patients with LTOT
- i8 Evidence for blood gas criteria for selection of COPD patients for LTOT
- i8 LTOT in hypercapnic COPD patients
- i9 Effects of LTOT on pulmonary haemodynamics in COPD patients
- i9 Effects of LTOT on sleep in COPD patients
- i9 Effects of LTOT on quality of life and neuropsychological function in COPD patients
- i9 LTOT in COPD patients and impact on hospital admission
- i9 Other effects of LTOT in COPD patients

i9 Evidence for use of LTOT in patients with other respiratory or cardiac disease

- i9 LTOT in patients with ILD
- i10 LTOT in patients with CF
- i10 LTOT in patients with pulmonary hypertension
- i10 LTOT in patient with neuromuscular or chest wall disorders
- i10 LTOT in patients with advanced cardiac failure
- i10 **Outcomes of LTOT in patients who continue to smoke**

i11 Referral and assessment of patients for LTOT

- i11 Patient information on referral for home oxygen assessment
- i11 Use of oximetry as a screening tool for patient selection for LTOT
- i11 Referral for home oxygen at hospital discharge
- i12 Use of pulse oximetry, ABGs and CBGs in assessment for LTOT
- i13 Management of hypercapnia during LTOT assessment
- i13 Use of LTOT: hours of use and flow rates
- i14 LTOT flow rates

- i14 **Patient education at time of assessment**
- i14 **Follow up of LTOT patients**
- i15 **Withdrawal of home oxygen**

i15 Nocturnal Oxygen Therapy

- i15 **NOT in COPD patients with nocturnal desaturation**
- i16 **NOT in patients with cardiac disease and nocturnal desaturation**
- i16 Effect of NOT on SDB in severe cardiac disease
- i16 Effect of NOT on cardiac function in severe cardiac disease
- i16 Effect of NOT on quality of life, activity and cognition in severe cardiac disease
- i17 Effect of NOT on healthcare utilisation or mortality
- i17 **NOT in patients with other respiratory diseases and nocturnal desaturation**
- i17 Use of NOT in patients with CF
- i17 Use of NOT in patients with ILD
- i18 Use of NOT in patients with neuromuscular weakness
- i18 Use of NOT in patients with Cheyne-Stokes respiration, obesity hypoventilation syndrome and overlap syndrome

i18 Ambulatory Oxygen Therapy

- i18 **AOT in patients not eligible for LTOT**
- i18 **Use of AOT during exercise**
- i19 **Long term impact of AOT**
- i19 **AOT in patients eligible for LTOT**
- i19 **Assessment for AOT**

i20 Palliative Oxygen Therapy

- i20 **Effects of POT in comparison with air**
- i20 **Effects of POT in comparison with other therapies such as opiates, fan therapy and cognitive behavioural therapy**



This article has been chosen by the Editor to be of special interest or importance and is freely available online.



This article has been made freely available online under the BMJ Journals Open Access scheme. See <http://thorax.bmj.com/site/about/guidelines.xhtml#open>



This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

www.publicationethics.org.uk



i21	Short Burst Oxygen Therapy
i21	Use of SBOT in respiratory disease
i22	Use of SBOT in CH
i22	Equipment for home oxygen therapy
i22	Oxygen source: concentrators, cylinders, liquid oxygen – description and indications for use
i22	Concentrators
i23	Home concentrators
i23	Transportable and portable concentrators
i23	Cylinder oxygen
i23	Liquid oxygen
i23	Comparison of different oxygen sources in clinical trials
i23	Use of portable oxygen to delivery ambulatory oxygen
i24	Use of portable oxygen to deliver LTOT
i24	Static cylinder use
i24	Oxygen delivery: nasal cannulae and masks, oxygen-conserving devices and trans-tracheal devices—description and indications for use
i24	Nasal cannulae and masks
i24	Oxygen-conserving devices
i25	Trans-tracheal oxygen
i25	Other equipment: trolleys and backpacks, humidifiers—descriptions and indications for use
i25	Humidification
i25	Carrying home oxygen: trolleys and backpacks

i25	Safety and Home Oxygen Therapy
i25	Smoking and home oxygen therapy
i26	Role of risk assessments
i26	Responsibilities of the oxygen supplier
i26	Role of fire and rescue services
i26	Trips and falls

i27 **Conclusion**

i27 **References**

i31 **Appendices**

i31	Appendix 1: Protocol for ambulatory oxygen therapy assessment
i34	Appendix 2: Assessment referral form
i35	Appendix 3: Assessment protocol for palliative oxygen
i36	Appendix 4: Risk assessment tools
i41	Appendix 5: Home oxygen order forms (HOOF) and home oxygen consent forms (HOOF) forms
i41	Appendix 6: Sample patient information leaflets
i42	Appendix 7: Practical points for removal of home oxygen
i43	Appendix 8: Guideline group members

Online appendices

	Web Appendix 9: PICO questions
	Web Appendix 10: Literature search details
	Web Appendix 11: Evidence tables
	Web Appendix 12: Home oxygen equipment

Receive regular table of contents by email.
Register using this QR code.

